Skip to content

Most Critically Ill Patients with COVID-19 Can Be Expected to Survive

In This Article

  • Published data on 1,591 ICU patients with COVID-19 in the Lombardy region of Italy is by far the largest ICU cohort reported to date
  • 88% of patients received mechanical ventilation within 24 hours of ICU admission
  • ICU mortality was higher for patients over 63 years of age and those who had hypertension
  • ICU mortality was 26% after limited follow-up time, with 58% of patients still in the ICU at the time of report
  • Countering the notion that respiratory failure in COVID-19 is a unique entity, the patients were broadly similar to ARDS patients in the LUNG-SAFE trial

On April 6, 2020, research published in JAMA reported on the largest ICU cohort of patients with COVID-19 to date. Camille Petri, MD, a fellow in Pulmonary and Critical Care Medicine at Massachusetts General Hospital, summarized and critiqued the publication in a fast literature update posted on April 8.

Study Subjects

The retrospective study involved 1,591 patients with confirmed COVID-19 admitted between February 20 and March 18, 2020, to any of 72 ICUs in the Lombardy region of Italy. The median age was 63 (range, 14–91) and 82% of patients were male. The ICU population consisted mostly of mild-to-moderate acute respiratory distress syndrome (ARDS) by Berlin criteria. 68% had one or more comorbidities, most commonly hypertension (49%), CVD (21%) or hypercholesterolemia (18%). Only 4% had COPD.

Respiratory Support

88% of patients received mechanical ventilation within 24 hours of ICU admission. During the first 24 hours:

  • Median PEEP was 14 cmH2O and the maximum was 22 cmH2O
  • 89% of patients required FiO2 ≥50%
  • Median PaO2/FiO2 was 160

Outcomes

As of March 25, 2020:

  • ICU mortality rate — 26% (15% in patients <64 years vs. 36% in older adults, P < .001)
  • Median ICU stay — 9 days

Commentary

There's been speculation that respiratory failure in COVID-19 patients has unique attributes. Yet the patients described here are broadly similar in age, comorbidities and respiratory parameters to those in the LUNG-SAFE trial, the largest observational study of ARDS in the pre–COVID-19 era.

This new study confirms that critically ill COVID-19 patients often require invasive mechanical ventilation with high levels of PEEP and FiO2. Mortality is unknown for now because 58% of patients remained in the ICU at the time of the report. However, overall mortality in LUNG-SAFE was 35%, and 28-day mortality in a Chinese COVID-19 ICU cohort was 28%. On that basis, it's reasonable to expect most critically ill patients with COVID-19 to survive.

View all COVID-19 updates

Visit the Division of Pulmonary and Critical Care Medicine at Mass General

Related topics

Related

During the COVID-19 pandemic, many novel approaches to acute respiratory distress syndrome (ARDS) have been suggested for immunomodulation and targeting the host response to SARS-CoV-2. However, these novel therapies must be evaluated in the context of the history of failed investigational therapies for ARDS.

Related

Are people who smoke or vape tobacco products at higher risk for severe COVID-19? In this Q&A, Jonathan Winickoff, MD, MPH, of the Massachusetts General Hospital Tobacco Research & Treatment Center, explains what we know and need to learn about coronavirus and smoking and vaping.